Nurix Therapeutics, Inc. (NRIX)
22.16
-0.19
(-0.85%)
USD |
NASDAQ |
Oct 12, 16:00
22.52
+0.36
(+1.62%)
After-Hours: 20:00
Nurix Therapeutics Shareholders Equity (Quarterly) : 402.63M for May 31, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| May 31, 2026 | 402.63M |
| February 28, 2026 | 480.89M |
| November 30, 2025 | 538.75M |
| August 31, 2025 | 372.25M |
| May 31, 2025 | 447.60M |
| February 28, 2025 | 480.92M |
| November 30, 2024 | 526.99M |
| August 31, 2024 | 376.86M |
| May 31, 2024 | 370.69M |
| February 29, 2024 | 168.75M |
| November 30, 2023 | 200.49M |
| August 31, 2023 | 233.82M |
| May 31, 2023 | 259.92M |
| February 28, 2023 | 274.05M |
| Date | Value |
|---|---|
| November 30, 2022 | 303.70M |
| August 31, 2022 | 342.54M |
| May 31, 2022 | 266.74M |
| February 28, 2022 | 305.92M |
| November 30, 2021 | 342.30M |
| August 31, 2021 | 375.22M |
| May 31, 2021 | 398.18M |
| February 28, 2021 | 270.13M |
| November 30, 2020 | 290.27M |
| August 31, 2020 | 307.62M |
| May 31, 2020 | -61.53M |
| February 29, 2020 | -69.80M |
| November 30, 2019 | -9.519M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 11.83B |
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 535.54M |
| Total Liabilities (Quarterly) | 132.91M |
| Debt to Equity Ratio | 0.1444 |
| Current Ratio | 6.338 |
| Net Debt Paydown Yield | -0.34% |